Trial Profile
A study evaluating the interpatient variability of plasma-posaconazole-concentrations in acute leukemia patients and allogeneic stem cell transplant recipients receiving Posaconazole oral suspension for primary antifungal prophylaxis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Posaconazole (Primary) ; Allogeneic stem cell therapy
- Indications Aspergillosis; Candidiasis; Chagas disease; Graft-versus-host disease; Leukaemia; Mycoses; Oropharyngeal candidiasis
- Focus Adverse reactions; Pharmacokinetics
- 06 Apr 2017 New trial record